文献速递血栓与止血造血干细胞移植与细胞治疗

血友病A供肝移植后受者未发生血友病A

Successful liver transplant from a hemophilia A donor with no development of hemophilia A in recipient.
PubMed 文献 · J Thromb Haemost · 2020-03-09

本文报告一例血友病A供者肝脏移植给无血友病A病史受者的病例并复习文献。受者移植后未发生血友病A,凝血因子VIII水平正常。据作者所知,这是人类第二例血友病A患者作为肝移植供者的病例,提示该人群或可成为扩大供者库的可行选择。

要点

  • 血友病A供者肝移植后受者未发生血友病A且因子VIII水平正常
  • 这是文献报道的第二例人类血友病A供者肝移植
  • 供者池扩大时或不应排除血友病A人群作为供者

核心结论

  • 血友病A供者的肝脏移植给无血友病A病史的受者后,受者未发生血友病A且因子VIII水平正常。

研究设计与样本

  • 病例报告并文献复习,报告一例血友病A供者肝脏移植给无血友病A病史受者的病例。

主要发现

  • 受者移植后未发生血友病A,因子VIII水平正常。
  • 据作者所知,这是人类第二例血友病A患者作为肝移植供者的病例。

关键数值与推荐

  • 血友病A诊断标准包括因子VIII活性低于正常40%、存在F8基因突变及排除血管性血友病。
  • 血友病A患者因内在凝血级联缺陷,特征性表现为PTT延长。

临床怎么用

  • 随着肝移植适应证扩大,需扩大供者名单,可能不应排除血友病A人群作为可行供者选择。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemophilia A is an X-linked inherited bleeding disorder caused by deficiency of coagulation factor VIII. Factor VIII is activated as part of the intrinsic coagulation cascade. It plays a crucial role as the cofactor in the intrinsic "tenase" complex activating factor X to assist in clot formation. Absence or mutation of this coagulation factor leads to excessive bleeding. Clinical manifestations of hemophilia relate to bleeding from impaired hemostasis, sequelae from bleeding, or complications of coagulation factor infusion. Diagnostic criteria for Hemophilia A include factor VIII activity level below 40% of normal, presence of a mutated F8 gene, and the absence of von Willebrand disease (F8 gene - Genetics Home Reference - NIH. https://ghr.nlm.nih.gov/gene/F8). Patients who have this intrinsic defect in the coagulation cascade have a characteristically prolonged PTT. It is theorized that the majority of factor VIII is synthesized mainly in the liver, by way of liver sinusoidal endothelial cells (Arruda VR. Haematologica. 2015;100(7):849-850). Extrahepatic production also occurs in the endothelial cells, kidneys, and lymphatic tissue. In 1969, Marchioro et al showed that transplantation of normal liver to hemophilia dog could normalize plasma factor VIII levels (Marchioro T L, Science. 1969;163(3863):188-190). These results were subsequently proven in humans. Liver transplantation from hemophilia A donors without factor VIII inhibitor is not commonly performed due to the perceived risk of developing hemophilia A in the recipient. There is currently limited literature aimed at elucidating this risk. We present a case of liver transplantation in a hemophilia A donor to a recipient with no history of hemophilia A with literature reviewis a case report, objective and method do not apply. OBJECTIVE AND METHOD: We did a case report and literature review of a liver transplant receipient fro ma hemohpila A donor. RESULTS: The receipient of the liver from hemophilia A donor did not develop hemophilia post transplant and had normal factor VIII levels. CONCLUSION: To our knowledge, this is only the second case in humans of hemophilia A patient as a donor in liver transplantation. As the indications for liver transplantation have expanded, there is a need to expand the donor list, and possibly not exclude this population as viable donor option.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kurian CJ, Drelich DA, Rizk S, et al. Successful liver transplant from a hemophilia A donor with no development of hemophilia A in recipient. J Thromb Haemost. 2020. PMID: 31997485. doi:10.1111/jth.14750

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。